Organovo Holdings 将来の成長

Future 基準チェック /26

Organovo Holdingsの収益は年間10.7%で減少すると予測されていますが、年間収益は年間43.8%で増加すると予想されています。EPS は年間15.2%で増加すると予想されています。

主要情報

-10.7%

収益成長率

15.2%

EPS成長率

Biotechs 収益成長	28.3%
収益成長率	43.8%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	11 Nov 2024

今後の成長に関する最新情報

Recent updates

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Feb 10

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Aug 24

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

May 10

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

Jan 04

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

May 28

業績と収益の成長予測

NasdaqCM:ONVO - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
3/31/2026	0	-15	N/A	N/A	1
3/31/2025	0	-15	N/A	N/A	1
9/30/2024	0	-13	-12	-12	N/A
6/30/2024	0	-14	-12	-12	N/A
3/31/2024	0	-15	-15	-15	N/A
12/31/2023	0	-19	-17	-17	N/A
9/30/2023	0	-19	-16	-16	N/A
6/30/2023	0	-18	-16	-15	N/A
3/31/2023	0	-17	-13	-12	N/A
12/31/2022	2	-12	-10	-9	N/A
9/30/2022	2	-12	-10	-10	N/A
6/30/2022	2	-12	-10	-9	N/A
3/31/2022	2	-11	-9	-8	N/A
12/31/2021	N/A	-12	-9	-9	N/A
9/30/2021	N/A	-11	-8	-7	N/A
6/30/2021	N/A	-17	-13	-12	N/A
3/31/2021	N/A	-17	-14	-13	N/A
12/31/2020	N/A	-17	-15	-14	N/A
9/30/2020	0	-18	-14	-14	N/A
6/30/2020	2	-15	-12	-12	N/A
3/31/2020	2	-19	-15	-15	N/A
12/31/2019	3	-23	-17	-17	N/A
9/30/2019	3	-26	-20	-20	N/A
6/30/2019	3	-26	-19	-19	N/A
3/31/2019	3	-27	-20	-20	N/A
12/31/2018	4	-27	-21	-21	N/A
9/30/2018	4	-28	-24	-23	N/A
6/30/2018	4	-32	N/A	-25	N/A
3/31/2018	5	-35	N/A	-29	N/A
12/31/2017	4	-38	N/A	-30	N/A
9/30/2017	4	-40	N/A	-31	N/A
6/30/2017	4	-40	N/A	-31	N/A
3/31/2017	4	-38	N/A	-29	N/A
12/31/2016	4	-36	N/A	-29	N/A
9/30/2016	3	-37	N/A	-29	N/A
6/30/2016	2	-39	N/A	-32	N/A
3/31/2016	1	-39	N/A	-29	N/A
12/31/2015	1	-38	N/A	-27	N/A
9/30/2015	1	-35	N/A	-25	N/A
6/30/2015	1	-32	N/A	-23	N/A
3/31/2015	1	-30	N/A	-20	N/A
12/31/2014	0	-29	N/A	-19	N/A
9/30/2014	0	-27	N/A	-19	N/A
6/30/2014	0	-29	N/A	-16	N/A
3/31/2014	0	-26	N/A	-16	N/A
12/31/2013	0	-35	N/A	-13	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ONVO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ONVO今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: ONVO今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: ONVOの収益 ( 43.8% ) US市場 ( 8.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: ONVOの収益 ( 43.8% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ONVOの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Organovo Holdings 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$0.75 loss

Consensus revenue estimates decrease by 25%, EPS upgraded

Recent updates

Organovo Holdings, Inc. Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

New minor risk - Share price stability

Consensus EPS estimates upgraded to US$0.75 loss

Organovo Holdings, Inc., Annual General Meeting, Nov 20, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Organovo Holdings Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

New minor risk - Share price stability

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Organovo Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $2.605728 million.

Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings

New minor risk - Shareholder dilution

New major risk - Market cap size

Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results

Consensus revenue estimates decrease by 25%, EPS upgraded

New major risk - Share price stability

New major risk - Market cap size

Organovo Holdings, Inc., Annual General Meeting, Oct 31, 2023

Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

Organovo Holdings, Inc. announced delayed annual 10-K filing

Is Organovo Holdings (NASDAQ:ONVO) In A Good Position To Invest In Growth?

Organovo Announces Target Validation Ahead of Schedule, Accelerating Timeline for First Crohn’s Disease Drug Candidates

High number of new and inexperienced directors

Here's Why We're Not Too Worried About Organovo Holdings' (NASDAQ:ONVO) Cash Burn Situation

Organovo Holdings, Inc., Annual General Meeting, Sep 07, 2022

Organovo Holdings, Inc. Successfully Advances Its First Inflammatory Bowel Disease Model to the Next Step of Target Discovery and Validation for Crohn’s Disease

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

BICO Reaches Beneficial and Sustainable Solution with Organovo

Organovo Holdings, Inc. Announces the Hiring of Curtis Tyree, PhD, as Sr. Vice President of Strategy and Business Development

Organovo Holdings, Inc. Guides on Patent Portfolio and Successful IPR Defense of Two Patents

BICO Group AB Announces Statement Regarding Counterclaims in Patent Lawsuit by Organovo Against Cellink

We're Hopeful That Organovo Holdings (NASDAQ:ONVO) Will Use Its Cash Wisely

High number of new and inexperienced directors

Organovo: New Strategy Targeting Internal Pipeline Development With Customized 3D Human Tissues Offers Upside

Organovo Holdings, Inc. Enter into Two Lease Agreements Between Company and San Diego Inspire 1, LLC

Organovo Regains Compliance with Nasdaq Minimum Bid Price Requirement

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Growth Index

Organovo Holdings, Inc.(NasdaqCM:ONVO) dropped from Russell Microcap Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘